Clinical trial · Interventional
High Flow Nasal Cannula After Esophagectomy
High Flow Nasal Cannula Oxygen Administration Versus Standard Care After Esophagectomy for Cancer: a Randomized Controlled Trial.
NCT05718284CI-TRIAL-00068367OSSIGENA1VunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will compare the effect of HFNC versus standard oxygen administration after elective esophagectomy for cancer.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Postoperative Acute Myocardial Infarction | — | UNRESOLVED | — |
| Postoperative Infection of Incision | — | UNRESOLVED | — |
| Postoperative Pneumonia | — | UNRESOLVED | — |
| Postoperative Pneumothorax | — | UNRESOLVED | — |
| Postoperative Pulmonary Atelectasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AIRVO2 | Device | — | UNRESOLVED |
| STANDARD CARE | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HFNC
- description
- Administration of high flow nasal oxygen after extubation for 48 hours
- interventionNames
- Device: AIRVO2
- type
- OTHER
- label
- STANDARD OXYGEN
- description
- Administration of oxygen through standard devices (nasal cannulae, venturi mask, none)
- interventionNames
- Other: STANDARD CARE
Primary outcomes (1)
- measure
- POST-OPERATIVE PULMONARY COMPLICATIONS
- timeFrame
- within 30 days after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * elective esophagectomy for cancer * METS≥4 * AGE 18-85 * Written informed consent Exclusion Criteria: * ASA\>3 * COPD≥ III stage according to GOLD criteria * FEV1\<50% * EF\<30% * NYHA\>2 * BMI\<17 or \>35 Kg/m2 * CKD with eGFR\<60 mL/min
References
Publications (3)
- BACKGROUNDDeana C, Vetrugno L, Stefani F, Basso A, Matellon C, Barbariol F, Vecchiato M, Ziccarelli A, Valent F, Bove T, Bassi F, Petri R, De Monte A. Postoperative complications after minimally invasive esophagectomy in the prone position: any anesthesia-related factor? Tumori. 2021 Dec;107(6):525-535. doi: 10.1177/0300891620979358. Epub 2020 Dec 15. PMID 33323061
- BACKGROUNDXia M, Li W, Yao J, Jin Y, Du G, Xu Q, Yi X, Nv X, Wu Y, He P, Wu W. A postoperative comparison of high-flow nasal cannula therapy and conventional oxygen therapy for esophageal cancer patients. Ann Palliat Med. 2021 Mar;10(3):2530-2539. doi: 10.21037/apm-20-1539. Epub 2021 Jan 21. PMID 33548991
- DERIVEDDeana C, Vecchiato M, Azzolina D, Turi S, Boscolo A, Pistollato E, Skurzak S, Amici O, Priolo S, Tonini S, Foti LS, Taddei E, Aceto P, Martino A, Ziccarelli A, Cereser L, Andreutti S, De Carlo S, Lirussi K, Barbariol F, Cammarota G, Polati E, Forfori F, Corradi F, Patruno V, Navalesi P, Maggiore SM, Lucchese F, Petri R, Bassi F, Romagnoli S, Bignami EG, Vetrugno L; Ossigena Study Group. Effect on post-operative pulmonary complications frequency of high flow nasal oxygen versus standard oxygen therapy in patients undergoing esophagectomy for cancer: study protocol for a randomized controlled trial-OSSIGENA study. J Thorac Dis. 2024 Aug 31;16(8):5388-5398. doi: 10.21037/jtd-24-575. Epub 2024 Aug 13. PMID 39268119